CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $39.38M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 5.54: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
29.16MGBP39.38M · vs all stocks (USD)
Revenue (TTM)
5.23MGBP7.06M · vs all stocks (USD)
Profit Margin
-8.73%vs Biotechnology peers
Beta
0.1210xvs all stocks
52-Week Change
-30.77%vs all stocks
Market Capitalization
29.16MGBP39.38M · vs all stocks (USD)
Enterprise Value
27.62MGBP37.30M · vs all stocks (USD)
Forward P/E
59.52xvs Biotechnology peers
Price to Sales (TTM)
5.58xvs Biotechnology peers
Price to Book (MRQ)
3.63xvs Biotechnology peers
Enterprise to Revenue
5.28xvs Biotechnology peers
Enterprise to EBITDA
-37.60xvs Biotechnology peers
Profit Margin
-8.73%vs Biotechnology peers
Operating Margin
-46.53%vs Biotechnology peers
Return on Assets (TTM)
-8.10%vs Biotechnology peers
Return on Equity (TTM)
-7.32%vs Biotechnology peers
Revenue (TTM)
5.23MGBP7.06M · vs all stocks (USD)
Revenue per Share (TTM)
0.0210GBPUpdated Aug 8, 2026Quarterly Revenue Growth
37.40%vs Biotechnology peers
Gross Profit (TTM)
3.19MGBP4.30M · vs all stocks (USD)
EBITDA (TTM)
-734.47KGBP-991.93K · vs all stocks (USD)
Net Income (TTM)
-456.41KGBP-616.40K · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.94MGBP-2.62M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.41MGBP-1.90M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 8, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.64MGBPFY2025 · Jun 30, 2025Cost of Goods Sold
1.78MGBPFY2025 · Jun 30, 2025Gross Profit
2.86MGBPFY2025 · Jun 30, 2025Operating Income
-1.12MGBP-1.51M · vs all stocks (USD)
Pre-tax Income
-715.12KGBPFY2025 · Jun 30, 2025Income Tax Expense
-18.86KGBPFY2025 · Jun 30, 2025Net Income
-696.25KGBPFY2025 · Jun 30, 2025EBIT
-623.13KGBPFY2025 · Jun 30, 2025EBITDA (Income Statement)
-696.54KGBPFY2025 · Jun 30, 2025Research & Development
127.35KGBPFY2025 · Jun 30, 2025Selling, General & Administrative
376.88KGBPFY2025 · Jun 30, 2025Other Operating Expenses
1.91MGBPFY2025 · Jun 30, 2025Non-operating Interest Expense
91.98KGBPFY2025 · Jun 30, 2025EPS (Basic)
-0.0031GBPFY2025 · Jun 30, 2025EPS (Diluted)
-0.0031GBPFY2025 · Jun 30, 2025Basic Shares Outstanding
227.87MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
227.87MSharesFY2025 · Jun 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Jun 30, 2025Operating Cash Flow
-1.89MGBPFY2025 · Jun 30, 2025Free Cash Flow
-1.89MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
4.78MGBPFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-715.12KGBPFY2025 · Jun 30, 2025Other Non-cash Items
-434.78KGBPFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
-752.28KGBPFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
14.18KGBPFY2025 · Jun 30, 2025Capital Expenditures
-6.30KGBPFY2025 · Jun 30, 2025Net Intangibles (CF)
-152.53KGBPFY2025 · Jun 30, 2025Net Acquisitions
-1.46MGBPFY2025 · Jun 30, 2025Net Investing Cash Flow
-1.47MGBPFY2025 · Jun 30, 2025Long-term Debt Issuance
950.00KGBPFY2025 · Jun 30, 2025Net Short-term Debt Issuance
0.00GBPFY2025 · Jun 30, 2025Net Financing Cash Flow
7.01MGBPFY2025 · Jun 30, 2025Shares Outstanding
258.78MSharesUpdated Aug 8, 2026Float Shares
140.53MSharesUpdated Aug 8, 2026% Held by Insiders
41.20%vs all stocks
% Held by Institutions
14.31%vs all stocks
Total Cash (MRQ)
3.12MGBP4.22M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0120GBPUpdated Aug 8, 2026Total Debt (MRQ)
939.16KGBP1.27M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1177xvs Biotechnology peers
Current Ratio (MRQ)
6.14xvs Biotechnology peers
Book Value per Share (MRQ)
0.0310GBPUpdated Aug 8, 2026Total Assets
12.13MGBP16.38M · vs all stocks (USD)
Total Current Assets
7.11MGBPFY2025 · Jun 30, 2025Total Liabilities
2.71MGBPFY2025 · Jun 30, 2025Total Non-current Assets
5.02MGBPFY2025 · Jun 30, 2025Total Non-current Liabilities
1.24MGBPFY2025 · Jun 30, 2025Total Current Liabilities
1.47MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents
4.78MGBPFY2025 · Jun 30, 2025Accounts Receivable
618.82KGBPFY2025 · Jun 30, 2025Inventory
800.15KGBPFY2025 · Jun 30, 2025Accounts Payable
513.33KGBPFY2025 · Jun 30, 2025Short-term Debt
112.11KGBPFY2025 · Jun 30, 2025Other Current Liabilities
250.00KGBPFY2025 · Jun 30, 2025Long-term Debt
881.35KGBPFY2025 · Jun 30, 2025Common Stock (Book)
2.59MGBPFY2025 · Jun 30, 2025Retained Earnings
-14.70MGBPFY2025 · Jun 30, 2025Total Shareholders' Equity
9.42MGBP12.72M · vs all stocks (USD)
52-Week High
23.00GBXUpdated Aug 8, 202652-Week Change
-30.77%vs all stocks
Beta
0.1210xvs all stocks
50-Day MA
9.67GBXUpdated Aug 8, 2026200-Day MA
10.98GBXUpdated Aug 8, 2026Avg 10-Day Volume
275.72KSharesUpdated Aug 8, 2026Avg 30-Day Volume
526.64KSharesUpdated Aug 8, 2026Diluted EPS (TTM)
-0.0031GBPUpdated Aug 8, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.54: safe zoneNotable
Altman Z-Score: 5.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $39.38M, lower than 95% of all stocks globallySignificant
Market cap (USD): 39,376,694.83Global P5: 269,387,740.27
Revenue is $7.06M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,059,982.009Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
ImmuPharma PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Context Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kala Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inspiration Healthcare Group plc
Tier 1ProductionApproval-Gated PipelineRule
Aptamer Group Plc
Tier 1ProductionApproval-Gated PipelineRule
Rua Life Sciences Plc
Tier 1ProductionApproval-Gated PipelineRule
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eco Animal Health Group PLC
Tier 1ProductionApproval-Gated PipelineRule
Creo Medical Group plc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Savannah Energy PLC
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Samhallsbyggnadsbolaget i Norden AB
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Techshine Electronics Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated